Ignite Creation Date:
2024-10-25 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06604000
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Goal Management Training GMT for Improvement of Cognitive Control Function After Acquired Brain Injury
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Goal Management Training GMT for Improvement of Cognitive Control Function After Acquired Brain Injury
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to investigate predictors of treatment outcome and the effect of individual treatment components of Goal Management Training GMT for improvement of cognitive control function in people with acquired brain injury ABI
Primary aim To identify demographic clinical and cognitive predictors of treatment response in Goal Management Training after acquired brain injury ABI
Secondary aims To investigate the effects of a extended cuing via a smartphone and b a booster module
All included participants will receive Goal Management Training in groups of 4-6 patients as implemented in a rehabilitation hospital setting St Olavs Hospital Trondheim University Hospital The standard treatment GMT Usual consists of 10 sessions delivered as 2 sessions a day one day per week over 5 weeks
All participants will be asked to complete self-report measures and performance-based cognitive testing at baseline T1 immediately after the main treatment period T2 at 6 months T3 and 1 year T4 after treatment
After baseline assessment 50 of participants will be randomized to receive extended cuing through a smartphone application GMT Cuing - intended to facilitate the effect of between-session tasks homework completed by the participants These participants will in addition to the standard treatment on a daily basis receive a message that says STOP as a reminder to do their home assignments
After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period 50 of the participants will be randomized to receive an additional booster module GMT Boost 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response The remaining 50 will receive no booster module GMT No Boost
Randomization will be carried out on treatment group-level all patients in the same group receive the same treatment The total anticipated sample size is N 116 patients
The Global Executive Composite GEC score derived from BRIEF-A will be used as the primary outcome measure A selection of other included measures will be used as secondary outcome measures
Primary aim To identify demographic clinical and cognitive predictors of treatment response in Goal Management Training after acquired brain injury ABI
Secondary aims To investigate the effects of a extended cuing via a smartphone and b a booster module
All included participants will receive Goal Management Training in groups of 4-6 patients as implemented in a rehabilitation hospital setting St Olavs Hospital Trondheim University Hospital The standard treatment GMT Usual consists of 10 sessions delivered as 2 sessions a day one day per week over 5 weeks
All participants will be asked to complete self-report measures and performance-based cognitive testing at baseline T1 immediately after the main treatment period T2 at 6 months T3 and 1 year T4 after treatment
After baseline assessment 50 of participants will be randomized to receive extended cuing through a smartphone application GMT Cuing - intended to facilitate the effect of between-session tasks homework completed by the participants These participants will in addition to the standard treatment on a daily basis receive a message that says STOP as a reminder to do their home assignments
After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period 50 of the participants will be randomized to receive an additional booster module GMT Boost 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response The remaining 50 will receive no booster module GMT No Boost
Randomization will be carried out on treatment group-level all patients in the same group receive the same treatment The total anticipated sample size is N 116 patients
The Global Executive Composite GEC score derived from BRIEF-A will be used as the primary outcome measure A selection of other included measures will be used as secondary outcome measures
Detailed Description:
The Global Executive Composite GEC score derived from BRIEF-A will be used as the primary outcome measure A selection of other included measures will be used as secondary outcome measures Data will be analyzed based on an intention-to-treat approach Penalized linear regression by the elastic net approach a combination of the Lasso and Ridge regression approaches will be used to identify demographic clinical and cognitive predictors of outcome at 6 months after treatment T3 which is the primary aim of the study For the secondary aim of investigating the differences in outcome for primary and secondary outcomes between GMT Cuing and GMT Usual and between GMT Boost and GMT No Boost linear mixed models LMMs will be used Data for all time points will be included but of primary interest are differences at T2 immediately after treatment for assessing the effect of cuing and at T3 6 months after treatment for the effect of boosting The LMMs can account for within-subject correlations due to repeated measurements In addition the investigators will perform exploratory moderation and mediation analyses across both treatment groups For the penalized regression models complete case analyses will be performed as long as the number of missing observations is small Otherwise imputation will be considered but imputation is not straightforward for variable selection models Linear mixed models can handle missing data for the outcome variable Considering multiple testing linked to several secondary outcomes p-values will be interpreted with care rather than using a formal p-value adjustment Results will be interpreted according to the magnitude of the group difference effect size as well as the p-values Data will be analyzed using IBM SPSS STATA and R
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None